Patent · US Expired

Recombinant 3-des-OH-cystatin C produced by expression in a procaryotic host cell

US5432264A · kind A · utility

10Cited by

0References

1Claims

0Family size

Assignee

Novo Nordisk A/S · DK

Inventors

Anders Grubb · Lund, SE
Ake Lundwall · Lund, SE
Magnus Abrahamson · Lund, SE
Henrik Dalboge · Avenue Madeleine, DK

Key dates

Filing date	Aug 13, 1992
Grant date	Jul 11, 1995
Priority date	—
Expiry date	Aug 13, 2012

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A recombinant cystatin C polypeptide or a derivative thereof, such as 3-des-hydroxy-cystatin C, is produced biosynthetically by fermentation of a microorganism into which plasmids containing a DNA-sequence coding for said polypeptide have been introduced. Preparations containing recombinant cystatin C, preferably 3-des-hydroxy-cystatin C, have a higher cystein proteinase inhibitor activity than native cystatin C, isolated from human fluids. Such preparations are useful in therapeutic treatments of patients suffering from different diseases, for example herbes simplex.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.